Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q1 EPS of $5.08, $1.66 better than the analyst estimate of $3.42. Revenue for the quarter came in at $320.3 million versus the consensus estimate of $244.65 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2022 EPS of $6.00, versus the consensus of $7.00. Fulgent Genetics, Inc. sees FY2022 revenue of $660 million, versus the consensus of $650 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.